/ Print /

Aine Cryts
Aine Cryts is a freelancer based in Boston. She is a frequent contributor to Managed Healthcare Executive on topics such as diabetes, oncology, hospital admissions and readmissions, senior patients, and health policy.
New Payment Model Improves Cancer Care at Oncology Group
CEO of a Pennsylvania-based oncology group shares how participating in a new value-based model is changing the care approach.
Burnout Hits Oncologists Hard, but Healthcare Systems Can Help
Burnout Hits Oncologists Hard, but Healthcare Systems Can Help
Healthcare systems stand to lose $6 million if burned out physicians choose to resign or work elsewhere. Here are some ways to curb burnout and its associated costs.
Improve Care Coordination in Cancer Care: 2 Key Focus Areas
When caring for cancer patients, improving care coordination in these two areas is key—and it can help reduce healthcare costs.
How Two Health Systems Use Predictive Analytics to Reduce Readmissions
Reducing hospital readmissions requires just the right mix of clinical expertise and predictive analytics. Here are two health systems that are hitting their stride.
Two Ways to Take Charge of CAR T-Cell Therapy Costs
Successful CAR T-cell therapy reimbursement begins with careful payer-provider collaboration and taking these two approaches.
Cancer Vaccine to Prevent Breast, Ovarian Cancer Recurrence Could be Close
In partnership with the several big-name cancer centers, one company has commenced clinical trials. Find out how this cancer vaccine would work.
CAR T-cell therapies in treating lymphoma: Pros and cons
Catherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Three things health execs need to know about CAR T-cell therapy
Here’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
Ovarian cancer could be next application for CAR T-cell therapy
While CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors.
Treating frail elderly patients with multiple myeloma requires different approach
Transplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.